Incentivizing Pharma Companies to Develop Lifesaving Drugs
OCT 21, 2017 | CONTAGION® EDITORIAL STAFF
James S. Lewis, PharmD, FIDSA, Co-Director of Antibiotic Stewardship, Oregon Health and Science University, shares different proposals shared in the health care community to incentivize pharmaceutical companies to develop needed drugs. Dr. Lewis warns that although antibiotic stewardship efforts are helping to slow down resistance, they will not be able to stop it from happening. With bacteria continually gaining resistance to available drugs, newer agents are desperately needed. In addition, Dr. Lewis also explains why susceptibility testing should be developed in parallel to new drugs that are being tested and developed.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Influenza A (H3N2) has caused most of the illnesses in this severe flu season, but influenza B is becoming increasingly responsible for more infections as the flu season continues to hit the United States.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512